by Halia Therapeutics | Aug 16, 2022 | Press Releases
SALT LAKE CITY (August 16, 2022) – Halia Therapeutics, the first biotechnology company to target NEK7 to block the assembly of the NLRP3 inflammasome complex, participated today in a fireside chat exploring approaches to innovate Alzheimer’s therapies at... by Halia Therapeutics | Aug 1, 2022 | Press Releases
SALT LAKE CITY (August 1, 2022) – Halia Therapeutics, a biotechnology company that has used a structure-based drug design strategy to discover a series of small molecule therapeutics targeting important mediators of inflammation, announced today that it will present a...